ITALY, Torino, March 18th, 2021. ELITechGroup is pleased to announce the release of SARS-CoV-2 Variants ELITe MGB® Kit. The Kit is for Research Use Only and is intended as a reflex test for the qualitative detection and discrimination of the mutations N501Y and E484K of the S gene of SARS-CoV-2 on the Sample-to Result-Platform ELITe InGenius® and on major PCR thermocyclers as well. The investigated mutations are relevant to discriminate the UK and NGR Variants and the ZA/BR Variants. The test will complement the menu of 41 CE-IVD certified infectious disease tests on ELITe InGenius® and specifically the panel for the respiratory infections. SARS-CoV-2 Variants ELITe MGB® Kit test was developed to provide the information to distinguish SARS-CoV-2 wild type and the most relevant SARS-CoV-2 variants. The endogenous Internal Control allows confirming the presence and quality of the sample material extracted.
Roberto Meda, Vice President MDx ELITechGroup, is excited to offer such an important multiplex Sample-to-Result solution for the detection of the mutations associated with increased infectivity and possible vaccine resistance. This achievement was made possible by the dedication and collaboration of all EG teams involved.
About ELITechGroup:
ELITechGroup is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents. By bringing together IVD specialty companies that offer innovative products and solutions, ELITechGroup has become a major contributor in advancing clinical diagnostics to laboratories in the proximity market, those operating closer to the patient.
